The Acute Intermittent Porphyria Drugs Market is expected to register a CAGR of 5.5% during the forecast period. The increased prevalence of metabolic problems, gastrointestinal troubles, and urinary tract concerns are all contributing to the expansion of the acute intermittent porphyria market.

Acute Intermittent Porphyria (AIP) is a rare metabolic condition, in which the enzyme hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase, is insufficient (PBGD). The accumulation of hazardous porphyrin precursors in the body can be caused by an enzyme shortage. However, a deficiency in itself is insufficient to cause illness symptoms, and most people with an HMBS gene mutation do not develop AIP symptoms. To cause the manifestation of symptoms, other elements such as endocrine effects, the use of certain medicines, excessive alcohol consumption, infections, and fasting or dietary changes are necessary.

The Acute Intermittent Porphyria market size is also increasing, due to rising prevalence of rare diseases, growing interest in better treatment, rapid increase in the number of geriatric population, healthcare insurance coverage, lifestyle changes, and increased awareness about health care technologies, as well as rapidly developing innovation.

According to the NCBI, the global prevalence of acute hepatic porphyria is expected to vary from one in 500 to one in 50,000 people. Acute Intermittent Porphyria (AIP) is the most prevalent type of porphyria in most areas, while ALA dehydratase-deficiency porphyria (ALAD) is the least common.

AIP appears after puberty, particularly in women (due to hormonal influences. Symptoms such as discrete attacks that last for two or more days are frequently characterized. The pain in the abdomen, which is sometimes accompanied by nausea, can be severe.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Regions Covered- Globally
• Competitive Landscape: Boston Scientific Corporation, Koninklijke Philips N.V., Siemens, Dahaner, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Acute Intermittent Porphyria DRUGS MARKET by Treatment

• Gonadotropin-Releasing Hormone Analogue
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market by End-Users 

• Hospitals & Clinics
• Research Centers

Global Acute Intermittent Porphyria Market by Region